Technical Analysis for PTGX - Protagonist Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 28.46 | -1.79% | -0.52 |
PTGX closed down 1.79 percent on Monday, March 18, 2024, on 1.14 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
20 DMA Resistance | Bearish | -1.79% | |
Pocket Pivot | Bullish Swing Setup | -1.79% | |
Fell Below 20 DMA | Bearish | 0.39% | |
Earnings Movers | Other | 0.39% | |
20 DMA Support | Bullish | -5.76% | |
Spinning Top | Other | -5.76% |
Alert | Time |
---|---|
Possible NR7 | about 7 hours ago |
Possible Inside Day | about 7 hours ago |
Down 2 % | about 11 hours ago |
Down 1% | about 11 hours ago |
Rose Above Previous Day's High | 3 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Ulcer Abdominal Pain Colitis Crohn's Disease Chemical Entities Hepcidin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Ulcer Abdominal Pain Colitis Crohn's Disease Chemical Entities Hepcidin
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 33.34 |
52 Week Low | 13.72 |
Average Volume | 793,184 |
200-Day Moving Average | 21.75 |
50-Day Moving Average | 27.27 |
20-Day Moving Average | 29.67 |
10-Day Moving Average | 29.94 |
Average True Range | 1.36 |
RSI (14) | 47.92 |
ADX | 34.62 |
+DI | 20.11 |
-DI | 16.95 |
Chandelier Exit (Long, 3 ATRs) | 29.26 |
Chandelier Exit (Short, 3 ATRs) | 30.40 |
Upper Bollinger Bands | 32.54 |
Lower Bollinger Band | 26.80 |
Percent B (%b) | 0.29 |
BandWidth | 19.34 |
MACD Line | 0.61 |
MACD Signal Line | 1.04 |
MACD Histogram | -0.4306 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 29.92 | ||||
Resistance 3 (R3) | 30.01 | 29.61 | 29.67 | ||
Resistance 2 (R2) | 29.61 | 29.24 | 29.57 | 29.59 | |
Resistance 1 (R1) | 29.04 | 29.01 | 28.84 | 28.95 | 29.51 |
Pivot Point | 28.64 | 28.64 | 28.55 | 28.60 | 28.64 |
Support 1 (S1) | 28.07 | 28.27 | 27.87 | 27.98 | 27.41 |
Support 2 (S2) | 27.67 | 28.04 | 27.63 | 27.33 | |
Support 3 (S3) | 27.10 | 27.67 | 27.25 | ||
Support 4 (S4) | 27.01 |